AI English summary of an SEC filing — figures as filed
Walmart WMTWalmart said it disclosed a proposed derivative lawsuit settlement under which insurance carriers would pay the company $123 million (before deduction of attorneys' fees and expenses awarded by the court), and the company would maintain certain corporate governance practices for at least 5 years, subject to court approval, on October 18, 2024.
Key points
AI summaryWalmart said it disclosed a proposed derivative lawsuit settlement under which insurance carriers would pay the company $123 million (before deduction of attorneys' fees and expenses awarded by the court), and the company would maintain certain corporate governance practices for at least 5 years, subject to court approval, on October 18, 2024.
The company said it would receive the settlement amount less attorneys' fees and expenses set by the court. Plaintiffs' counsel plans to request fees of up to 20% of the settlement fund and litigation expenses of up to $600,000, and individual shareholders will not receive any direct payment.
The company said the lawsuit alleges that current and former directors and officers breached their duty to oversee the distribution and dispensing of prescription opioids, and that the board formed a special litigation committee on May 5, 2023. The defendants deny any wrongdoing, the company said.
The company said the court will hold the settlement fairness hearing on December 20, 2024 at 1:30 p.m. The plaintiffs allege that the company was harmed, including by its agreement to pay up to $3.1 billion to resolve opioid lawsuits, the company noted.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Settlement amount $123 million and approval conditions
Walmart said it disclosed a proposed derivative lawsuit settlement under which insurance carriers would pay the company $123 million (before deduction of attorneys' fees and expenses awarded by the court), and the company would maintain certain corporate governance practices for at least 5 years, subject to court approval, on October 18, 2024.
Source · Based on the filing body and exhibits
Settlement proceeds structure and attorneys' fee cap
The company said it would receive the settlement amount less attorneys' fees and expenses set by the court. Plaintiffs' counsel plans to request fees of up to 20% of the settlement fund and litigation expenses of up to $600,000, and individual shareholders will not receive any direct payment.
Source · Based on the filing body and exhibits
Litigation issues and special litigation committee
The company said the lawsuit alleges that current and former directors and officers breached their duty to oversee the distribution and dispensing of prescription opioids, and that the board formed a special litigation committee on May 5, 2023. The defendants deny any wrongdoing, the company said.
Source · Based on the filing body and exhibits
Settlement hearing schedule and $3.1 billion settlement background
The company said the court will hold the settlement fairness hearing on December 20, 2024 at 1:30 p.m. The plaintiffs allege that the company was harmed, including by its agreement to pay up to $3.1 billion to resolve opioid lawsuits, the company noted.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…